Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02166684
Other study ID # P9608
Secondary ID
Status Completed
Phase N/A
First received June 16, 2014
Last updated December 19, 2014
Start date September 2014
Est. completion date December 2014

Study information

Verified date December 2014
Source TNO
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

The study aims to evaluate whether do-it-yourself devices for self-measuring health parameters by subjects can be used for obtaining useful data in scientific studies.

Besides, the study aims to evaluate if increased awareness of own health status by self-monitoring health parameters also serves as motivational instrument for changing health behaviour.


Description:

During this three month study subjects will self-monitor multiple parameters of health with do-it-yourself devices. Subjects are supplied with devices for measuring physical activity, food intake, body weight, blood pressure, blood glucose level and blood cholesterol level. These devices have to be used with varying frequencies, ranging from continuously to only a baseline- and endpoint measure.

Subjects will have to upload data resulting from these self-measures to an encoded account on an online portal.

At any time during the study, subjects can log-on to this portal, to gain insight in their own health parameters.

Only encoded subject data can be exported from this portal for data analysis.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 67 Years
Eligibility Inclusion Criteria:

1. Age ranging from 18 - 67 years

2. Desk-job and not exceed the Dutch Standard of Healthy Physical Activity of 5 hours/week

3. Healthy as assessed by the Health and Lifestyle questionnaire

4. Body mass index: 20 - 30 kg/m2

5. Able to use self-monitoring devices

6. Voluntary participation

7. Having given written informed consent

8. Willing to comply with study procedures

9. Willingness to share pseudonymised data on food intake with external party Fatsecret (food intake app provider)

10. Willingness to share pseudonymised data on blood glucose, blood pressure, physical activity and body weight with external party Medisana (provider of measurement Toolkit)

11. Willingness to share pseudonymised data on food intake, blood glucose, blood cholesterol, blood pressure, physical activity and body weight with the Nutrition Research Cohort (NRC) database

12. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data by TNO

13. Have a desktop or laptop with internet access at home

14. Subjects should own a Smartphone with Bluetooth that runs either a recent version of iOS or Android.

15. Having one of the TNO locations in Delft, Den Haag or Rijswijk as posting

Exclusion Criteria:

1. Use of concomitant medication including medication known for its effects on blood glucose, cholesterol or insulin

2. Having a history of medical or surgical events that may significantly affect the study outcome, including physical limitations or cardio-vascular events

3. Having a pacemaker

4. Currently suffering from diabetes type I or type II as determined by the general practitioner

5. Reported slimming or medically prescribed diet

6. Physical, mental or practical limitations in using computerized systems

7. Alcohol consumption > 28 units/week for males and > 21 units (drinks)/week for females

8. Reported unexplained weight loss or gain of > 2 kg in the three months prior to the pre-study screening

9. Partner or first or second-degree relative from TNO personnel stationed at a TNO location in Zeist, Leiden, Hoofddorp or Soesterberg where the study protocol was developed.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Device:
Do-it-yourself devices
Medisana Vifit is worn every day all-day by each subject Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure. Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks Subjects use Medisana BS 440 BT scale daily In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app. Subjects self-measure fasting blood glucose twice per week for 13 weeks. Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120.

Locations

Country Name City State
Netherlands Netherlands Organisation for Applied Scientific Research (TNO) Zeist Utrecht

Sponsors (1)

Lead Sponsor Collaborator
W.J. Pasman

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of complete datasets percentage is calculated for total complete datasets as well as complete datasets per device end of study (after 13 weeks) No
Primary Health behaviour change established by comparing baseline values for food intake and physical activity as measured by a Lifestyle-questionnaire baseline and after 13 weeks (end of study) No
Primary User-experiences with do-it-yourself devices as measured by a questionnaire on user-experiences as well as focus group interviews for more in-depth information after 13 weeks (end of study) No
Secondary self-measured blood pressure baseline + weekly from week 1 until week 13 No
Secondary self-recorded food intake every of the three periods, food intake will be recorded at two week days and one weekend day week 1, week 7 and week 13 No
Secondary daily physical activity wearable activity tracker that measures number of steps taken, duration of activity and estimates the number of calories burned daily during 13 weeks (baseline - end of study) No
Secondary Fasting blood glucose level self-assessed after overnight fast (at least eight hours) twice per week at baseline and from week 1 until 13 No
Secondary body weight self-assessed with a smart scale that also calculates BMI and body fat percentage three times per week at baseline and from week 1 to 13 No
Secondary blood cholesterol levels self-assessed baseline and after 13 weeks (end of study) No
Secondary oral glucose tolerance test (OGTT) do-it-yourself version of OGTT; blood glucose levels will be assessed using the Medisana MediTouch 2 week 1 and week 13 No
Secondary change in vitality as assessed with a vitality questionnaire (Vita-16) baseline and week 13 No
Secondary change in subjective stress level as assessed with DASS-21 questionnaire baseline and week 13 No
Secondary change in subjective quality of life as assessed with RAND-36 questionnaire baseline and week 13 No
See also
  Status Clinical Trial Phase
Completed NCT04488796 - STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers N/A
Completed NCT05216159 - Mobile Health-Health Action Process Approach Based Intervention on Sedentary Behaviour and Stress in Office Workers N/A
Completed NCT03760393 - A Combined HAPA and mHealth Intervention to Reduce Sedentary Behaviour in University Students N/A
Completed NCT03461926 - A Combined HAPA and mHealth Intervention to Increase Non-Sedentary Behaviours in Office-Working Adults N/A
Not yet recruiting NCT05115253 - Reducing Sedentary Behaviour in Office Workers With a HAPA mHealth Intervention and a Just In-Time Adaptive Intervention N/A